| Title |
Immunocytokines: a review of molecules in clinical development for cancer therapy
|
|---|---|
| Published in |
Clinical Pharmacology : Advances and Applications, August 2013
|
| DOI | 10.2147/cpaa.s49231 |
| Pubmed ID | |
| Authors |
Thomas List, Dario Neri |
| Abstract |
The concept of therapeutically enhancing the immune system's responsiveness to tumors is long standing. Several cytokines have been investigated in clinical trials for their therapeutic activity in cancer patients. However, substantial side effects and unfavorable pharmacokinetic properties have been a major drawback hampering the administration of therapeutically relevant doses. The use of recombinant antibody-cytokine fusion proteins promises to significantly enhance the therapeutic index of cytokines by targeting them to the site of disease. This review aims to provide a concise and complete overview of the preclinical data and clinical results currently available for all immunocytokines having reached clinical development. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 138 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| France | 1 | <1% |
| Belgium | 1 | <1% |
| Unknown | 135 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 28 | 20% |
| Student > Ph. D. Student | 21 | 15% |
| Student > Master | 20 | 14% |
| Other | 15 | 11% |
| Student > Bachelor | 8 | 6% |
| Other | 13 | 9% |
| Unknown | 33 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 31 | 22% |
| Biochemistry, Genetics and Molecular Biology | 22 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 12 | 9% |
| Medicine and Dentistry | 11 | 8% |
| Chemistry | 9 | 7% |
| Other | 18 | 13% |
| Unknown | 35 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 March 2024.
All research outputs
#3,274,808
of 25,374,917 outputs
Outputs from Clinical Pharmacology : Advances and Applications
#28
of 179 outputs
Outputs of similar age
#27,188
of 210,078 outputs
Outputs of similar age from Clinical Pharmacology : Advances and Applications
#2
of 10 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 179 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 210,078 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 8 of them.